of - 医索

找到约 1284 条结果

Abstract LBA509Rates of pathologic complete response(pCR)after neoadjuvant datopotomab deruxtecan(Dato-DXd) Results from the l-SPY 2.2trial

医客学院 - 会议报告集

Abemaciclib plus fulvestrant vs fulvestrant alone for HR HER2-advanced breast cancer following progression onprior CDK46 inhibitor plus endocrine therapy Primaryoutcome of the Phase 3 postMONARCH

医客学院 - 会议报告集

slides-The_impact_of_adjuvant_endocrine_therapy_AET_omiss

医客学院 - 会议报告集

slides-Rates_of_pathologic_complete_response_pCRafter_neo

医客学院 - 会议报告集

slides-Association_of_MammaPrint_index_and_3year_outcome_.

医客学院 - 会议报告集

Taiwan National Lung Cancer Early Detection Program for HeavySmokers and Non-smokers with Family History of Lung Cancer

医客学院 - 会议报告集

Sparking the ConversationIntegrating ctDNA and Quality ofLife in Adjuvant Lung Cancer Care

医客学院 - 会议报告集

slides-Overall_survival_of_adebrelimab_plus_chemotherapy_.

医客学院 - 会议报告集

Safety and efficacy of osimertinib plus consolidativestereotactic ablative radiation(SABR) inadvanced EGFR mutant non-small cell lungcancer(NSCLC)results from a multi-center Phase ltrial

医客学院 - 会议报告集

Phase lalb trial of zongertinib (Bl 1810631),aHER2-specific tyrosine kinase inhibitor in patients withHER2 aberration-positive solid tumors updatedPhase la data from Beamion LUNG-1, includingprogression-

医客学院 - 会议报告集

今日实时热搜